Combine Shockwave Therapy with PRP for Tendinopathy

Combining extracorporeal shockwave therapy (ESWT) with platelet-rich plasma (PRP) injections for tendinopathy involves utilizing ESWT to disrupt recalcitrant scar tissue and upregulate cellular receptors, followed by targeted PRP delivery to supply concentrated autologous growth factors. Clinicians typically sequence ESWT either immediately before the PRP injection or across several priming sessions, leveraging shockwave mechanotransduction to enhance tissue permeability and local recruitment of regenerative cytokines.

Biological Rationale for Dual-Modality Tendinopathy Therapy

Chronic tendinopathies—such as recalcitrant lateral epicondylitis, Achilles tendinopathy, patellar tendinopathy, and plantar fasciitis—are characterized by hypocellularity, disordered collagen matrices, and compromised local vascularity. Single-modality treatments frequently face hurdles due to the hypovascular nature of mature tendon tissue, which limits endogenously circulating repair factors from reaching the site of pathology.

Combining physical mechanotransduction via shockwave devices with biological augmentation addresses these tissue limitations through distinct, complementary biological pathways:

• Extracorporeal Shockwave Therapy (ESWT): Acoustic shockwaves deliver targeted mechanical stress to degenerate tendon tissue. This triggers microtrauma that upregulates vascular endothelial growth factor (VEGF), promotes neovascularization, breaks down fibrotic adhesions, and transiently increases cell membrane permeability.
• Platelet-Rich Plasma (PRP): Autologous biologics supply a concentrated mixture of bioactive proteins, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and insulin-like growth factor (IGF-1). These factors drive fibroblast proliferation, extracellular matrix synthesis, and modulated tissue remodeling.

When combined, shockwave therapy prepares the tissue bed by micro-disrupting hypercellular scar tissue and stimulating local cellular receptors, allowing the subsequently injected PRP to distribute more uniformly and interact with responsive tenocytes.

Sequencing Protocols: Pre-Treatment Priming vs. Concurrent Delivery

Selecting the appropriate sequence depends on tissue chronicity, anatomical depth, and patient tolerance. Clinicians utilizing regenerative devices in combination with biological autologous concentrates generally adopt one of three sequencing strategies:

1. The Pre-Injection Priming Protocol

In this multi-week approach, the patient receives 2 to 3 sessions of low-to-medium energy shockwave therapy spaced 7 days apart prior to the PRP injection. The objective is to induce local hyperemia, soften recalcitrant tissue, and upregulate cell-surface receptors before biological delivery. The final PRP injection is administered 3 to 7 days after the last ESWT session.

2. Same-Day Combination Protocol

For streamlined scheduling, clinicians apply a targeted radial or focused shockwave application directly prior to ultrasound-guided PRP injection during a single clinical encounter. ESWT is delivered first to increase tissue permeability and provoke an acute mechanical signaling response. PRP is injected immediately afterward into the targeted degenerative hypocellular area.

3. Post-Injection Reactivation Protocol

In recalcitrant non-responders, an initial PRP injection is followed 4 to 6 weeks later by low-energy shockwave sessions. This strategy aims to re-engage mechanical signaling pathways as the early biological healing phase plateaus, accelerating extracellular matrix remodeling without disrupting initial fibrin clot formation.

Clinical Caution: Shockwave therapy should not be applied directly over a recent PRP injection site during the first 2 to 3 weeks post-procedure. High mechanical energy delivered immediately after injection can disrupt early structural fibrin scaffold creation and cause unwanted mechanical shear stress on fragile newly formed capillary networks.

Protocol Selection & Clinical Checklist

To ensure consistent patient preparation, tissue targeting, and safety when combining ESWT and PRP, clinical teams should standardise their approach using a structured checklist:

• Diagnostic Verification: Confirm chronic tendinopathy and rule out acute full-thickness tears or calcification patterns requiring surgical intervention via ultrasound or MRI.
• Medication Management: Instruct patients to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) 7 to 10 days prior to procedure initiation to preserve platelet activation pathways.
• Anesthetic Protocol: Avoid direct local infiltration of high-volume local anesthetics (e.g., lidocaine, bupivacaine) into the intended PRP target zone immediately before injection, as local anesthetics lower platelet viability and alter pH levels.
• ESWT Parameter Setting: Calibrate energy flux density (EFD) based on tissue depth; lower EFD ranges are preferred for superficial tendons (e.g., epicondyles), whereas higher EFD ranges are suited for deeper structures (e.g., proximal hamstring or gluteal tendons).
• Biological Processing: Utilize dual-spin centrifugation systems to achieve predictable platelet concentration yields tailored to the specific anatomical site (e.g., leukocyte-poor PRP for intra-articular or focal tendinous regions).
• Post-Procedure Rehabilitation: Establish a progressive, eccentric loading rehab program starting 10 to 14 days post-injection, avoiding aggressive stretching during the acute inflammatory phase.

Clinical Considerations by Anatomical Site

Different anatomical structures present distinct challenges regarding vascularity, depth, and biomechanical stress. Clinicians in sports medicine practices and orthopedic practices tailor their dual-modality protocols based on location:

• Lateral Epicondylitis: Superficial location allows lower energy shockwave application prior to leukocyte-poor PRP injection. Focus on the origin of the extensor carpi radialis brevis (ECRB).
• Achilles Tendinopathy: For mid-substance pathology, apply radial ESWT along the calf complex and tendon body prior to ultrasound-guided intratendinous PRP administration. Avoid high energy shockwave over non-insertional tendon tissue showing severe cyst formation.
• Plantar Fasciitis: Requires higher energy density settings to penetrate the thick plantar aponeurosis. Combining focused shockwave with PRP yields superior long-term pain resolution compared to monotherapy in recalcitrant cases.

Operational and Economic Integration for Medical Practices

For practice managers and procurement officers, integrating dual-modality protocols requires balancing clinical efficacy with workflow optimization, equipment ROI, and transparent patient cost structures.

Equipment and Consumable Optimization

Executing dual-modality protocols efficiently relies on maintaining reliable hardware and consistent supply chains. Capital equipment expenditures include a focused or radial shockwave unit alongside a high-yield centrifuge system. Consumable costs primarily consist of single-use PRP processing kits, ultrasound kits, disposable acoustic coupling gel, and replacement handpiece projectiles or transmitters for shockwave units.

Workflow and Scheduling Efficiency

To minimize treatment room bottlenecks, practices can structure multi-modality patient visits as follows:

1. Preparation (10 minutes): Blood draw conducted by clinical support staff while the patient completes outcome questionnaires.
2. Biological Processing & ESWT (15–20 minutes): Centrifugation occurs concurrently with the physician or trained staff administering the shockwave therapy session.
3. Targeted Injection (10–15 minutes): Physician performs ultrasound-guided PRP injection into the primed anatomical target.

Packaging and Financial Modeling

Because combined biological and energy-based therapies are typically cash-pay procedures, practices achieve higher conversion rates by bundling shockwave therapy and PRP into comprehensive treatment packages rather than billing individual modalities per visit. Bundled packaging improves compliance with multi-visit shockwave sequences and provides clear expectations regarding total out-of-pocket investment.

What This Means for Your Practice

Adopting a combined shockwave and PRP protocol allows your clinic to offer evidence-informed options for patients suffering from chronic, recalcitrant tendinopathies.

• Audit Current Capabilities: Evaluate whether your existing centrifuge equipment provides suitable platelet concentration and leukocyte control, and determine if your shockwave platform provides adjustable energy flux densities for variable tendon depths.
• Standardize Clinical Pathways: Implement pre-procedure medication hold lists and consistent scheduling blocks for dual-modality visits.
• Train Clinical Staff: Ensure clinical support personnel are proficient in blood drawing, centrifuge operation, and patient post-procedure guidelines.
• Update Patient Consent & Education: Develop collateral explaining the synergistic rationale of combining acoustic physical energy with autologous biologics.

To explore high-yield PRP systems, focused or radial shockwave technology platforms, and clinical integration support tailored to your practice, contact Dallas Regenerative Solutions to schedule an operational consultation.